Amgen said that it will no longer develop an early-stage obesity pill, and will instead focus on an injectable candidate that’s seen as a potential Wegovy and Zepbound competitor.
Click here to view original post
Click Here to Publish/Feature Your Company or Product News with Biotech Networks
